Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PTI-6D2 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PTI-6D2 | DRUG | monoclonal antibody |
Inclusion Criteria: * Patients must have histologically or clinically confirmed malignant melanoma of one of the following stages (according to 2002 American Joint Committee on Cancer criteria: Appendix C): Unresectable Stage III disease or Stage IV disease * Patients must have measurable disease a...
Top 20 of 52 competitors
PTI-6D2 is an investigational small molecule developed by Filana Therapeutics, Inc. for metastatic melanoma. It has been studied as a radioisotope-labeled agent in a Phase 1 dose escalation and safety trial. The compound is not approved and remains in clinical development.
PTI-6D2 is being evaluated for the treatment of metastatic melanoma. Its only clinical study to date was a Phase 1 dose escalation and safety trial in patients with metastatic melanoma. The drug is investigational and has not been approved for any indication.
PTI-6D2 is being developed by Filana Therapeutics, Inc., which trades under the ticker FLNA. The company is the sponsor of the clinical program for this small molecule in metastatic melanoma.
PTI-6D2 is in Phase 1 development. Its single clinical trial, NCT00734188, was a Phase 1 dose escalation and safety study in metastatic melanoma that has been completed. The drug is investigational and has not received FDA approval.
PTI-6D2 has been studied in one clinical trial, NCT00734188, titled Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma. The Phase 1 trial enrolled 21 patients in Israel and is completed. No active trials are ongoing.